<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2804257299
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Amiroic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMINOCAPROIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        236
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3943.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="M/s Annora Pharma Private Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            M/s Annora Pharma Private Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Amiroic is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required.</p><p>Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix.</p><p>Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See <u>WARNINGS</u>.)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Amiroic should not be used when there is evidence of an active intravascular clotting process.</p><p>&nbsp;</p><p>When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering Amiroic.</p><p>&nbsp;</p><p>The following tests can be applied to differentiate the two conditions:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Platelet count is usually decreased in DIC but normal in primary fibrinolysis.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC. Amiroic must not be used in the presence of DIC without concomitant heparin. <strong>Precautions</strong></p><p>General</p><p>Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The drug should NOT be administered without a definite diagnosis and/or laboratory finding indicative of hyperfibrinolysis (hyperplasminemia).1</p><p>&nbsp;</p><p>Inhibition of fibrinolysis by aminocaproic acid may theoretically result in clotting or thrombosis. However, there is no definite evidence that administration of aminocaproic acid has been responsible for the few reported cases of intravascular clotting which followed this treatment. Rather, it appears that such intravascular clotting was most likely due to the patient&#39;s pre-existing clinical condition, e.g., the presence of DIC. It has been postulated that extravascular clots formed <em>in vivo </em>may not undergo spontaneous lysis as do normal clots.</p><p>&nbsp;</p><p>Reports have appeared in the literature of an increased incidence of certain neurological deficits such as hydrocephalus, cerebral ischemia, or cerebral vasospasm associated with the use of antifibrinolytic agents in the treatment of subarachnoid haemorrhage (SAH). All of these events have also been described as part of the natural course of SAH, or as a consequence of diagnostic procedures such as angiography. Drug relatedness remains unclear.</p><p>&nbsp;</p><p>Aminocaproic acid should not be administered with Factor IX Complex concentrates or Anti-Inhibitor Coagulant concentrates, as the risk of thrombosis may be increased.</p><p>Laboratory Tests</p><p>The use of aminocaproic acid should be accompanied by tests designed to determine the amount of fibrinolysis present. There are presently available: (a) general tests such as those for the determination of the lysis of a clot of blood or plasma; and (b) more specific tests for the study of various phases of the fibrinolytic mechanisms. These latter tests include both semiquantitative and quantitative techniques for the determination of profibrinolysin, fibrinolysin, and antifibrinolysin.</p><p>Drug Laboratory Test Interactions</p><p>Prolongation of the template bleeding time has been reported during continuous intravenous infusion of aminocaproic acid at dosages exceeding 24 g/day. Platelet function studies in these patients have not demonstrated any significant platelet dysfunction. However, <em>in vitro </em>studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) aminocaproic acid inhibits ADP and collagen- induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner. Following a 10 g bolus of aminocaproic acid, transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained. The concentration of aminocaproic acid necessary to maintain inhibition of fibrinolysis is 0.99 mMol/L or 0.13 mg/mL. Administration of a 5 g bolus followed by 1 to 1.25 g/hr should achieve and sustain plasma levels of</p><p>0.13 mg/mL. Thus, concentrations which have been obtained <em>in vivo </em>clinically in patients with normal renal function are considerably lower than the <em>in vitro </em>concentrations found to induce abnormalities in platelet function tests. However, higher plasma concentrations of aminocaproic acid may occur in patients with severe renal failure.</p><p>Carcinogenesis, Mutagenesis, Impairment of Fertility</p><p>Long-term studies in animals to evaluate the carcinogenic potential of aminocaproic acid and studies to evaluate its mutagenic potential have not been conducted. Dietary administration of an equivalent of the maximum human therapeutic dose of aminocaproic acid to rats of both sexes impaired fertility as evidenced by decreased implantations, litter sizes and number of pups born.</p><p>Pregnancy</p><p><em>Pregnancy Category C</em>. Animal reproduction studies have not been conducted with aminocaproic acid. It is also not known whether aminocaproic acid can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Aminocaproic acid should be given to a pregnant woman only if clearly needed.</p><p>&nbsp;</p><p>Nursing Mothers</p><p>It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when aminocaproic acid is administered to a nursing woman.</p><p>Pediatric Use</p><p>Safety and effectiveness in pediatric patients have not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>An identical dosage regimen may be followed by administering Amiroic as follows:</p><p>&nbsp;</p><p>For the treatment of acute bleeding syndromes due to elevated fibrinolytic activity, it is suggested that</p><p>20 milliliter of Amiroic (5 g) be administered during the first hour of treatment, followed by a continuing rate of 5 milliliter of Amiroic (1.25 g) per hour. This method of treatment would ordinarily be continued for about 8 hours or until the bleeding situation has been controlled.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Aminocaproic acid is generally well tolerated. The following adverse experiences have been reported:</p><p><strong>General: </strong>Edema, headache, malaise.</p><p><strong>Hypersensitivity Reactions: </strong>Allergic and anaphylactoid reactions, anaphylaxis.</p><p><strong>Cardiovascular: </strong>Bradycardia, hypotension, peripheral ischemia, thrombosis.</p><p><strong>Gastrointestinal: </strong>Abdominal pain, diarrhea, nausea, vomiting.</p><p><strong>Hematologic: </strong>Agranulocytosis, coagulation disorder, leukopenia, thrombocytopenia.</p><p><strong>Musculoskeletal: </strong>CPK increased, muscle weakness, myalgia, myopathy (see <strong><u>WARNINGS</u></strong>), myositis, rhabdomyolysis.</p><p><strong>Neurologic: </strong>Confusion, convulsions, delirium, dizziness, hallucinations, intracranial hypertension, stroke, syncope.</p><p><strong>Respiratory: </strong>Dyspnea, nasal congestion, pulmonary embolism.</p><p><strong>Skin: </strong>Pruritis, rash.</p><p><strong>Special Senses: </strong>Tinnitus, vision decreased, watery eyes.</p><p>&nbsp;</p><p><strong>Urogenital: </strong>BUN increased, renal failure. There have been some reports of dry ejaculation during the period of aminocaproic acid treatment. These have been reported to date only in hemophilia patients who received the drug after undergoing dental surgical procedures. However, this symptom resolved in all patients within 24 to 48 hours of completion of therapy.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Dispense in Tight Containers; Do Not Freeze.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; This medicine does not require any special storage conditions.</p><p>&middot;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp; What Amiroic contains</p><p>The active substance is Aminocaproic acid.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each 5 mL of solution contains 1.25 g of aminocaproic acid USP.</p><p>&nbsp;</p><p><strong>The other ingredients are: </strong>Methyl paraben, Propyl paraben, Edetate disodium dihydrate (Titriplex III Emprove), Saccharin Sodium, Sorbitol solution (Sorbidex 71122), Anhydrous Citric Acid (Powder, Emprove), Raspberry flavor AP-888-075-9</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Clear, colorless to slightly yellow color solution with raspberry flavor.
How supplied:
Amiroic is Supplied in 8 Fl. oz. (236.5 mL) in HDPE Bottle Pack.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Saudi Amarox Industrial Company </strong>Al Jamiah Street, Al Malaz District Riyadh 12629, Saudi Arabia</p><p>Tel &amp; Fax: +966 11 226 8850</p><p>Manufacturer</p><p>Annora Pharma Private Limited &ndash; India.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in April 2023 , Version 1. 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يعتبر أميرويك معلق فموي عامل مضاد لانحلال الفايبرين حيث يساعد في تعزيز الإرقاء عندما يتسبب انحلال الفايبرين في النزيف. في المواقف التي تهدد الحياة، قد يلزم نقل مكونات الدم المناسبة وتدابير الطوارئ الأخرى.</p><p dir="RTL">قد يترافق النزف الانحلالي للفايبرين في كثير من الأحيان مع المضاعفات الجراحية التالية لجراحة القلب (مع أو بدون إجراءات تحويل مسار القلب) والتحويلة الأذنية؛ اضطرابات الدم مثل نقص الصفيحات (فقر الدم اللاتنسجي المصاحب)؛ المشيمة الحادة والمهددة للحياة؛ تليف الكبد. وأمراض الأورام مثل سرطان البروستاتا والرئة والمعدة وعنق الرحم.</p><p dir="RTL">قد يساهم انحلال الفايبرين البولي &quot;عادة ما يكون ظاهرة فسيولوجية طبيعية&quot; في حدوث نزيف فايبرينيي مفرط في المسالك البولية مرتبط ببيلة دموية جراحية (بعد استئصال البروستاتا واستئصال الكلية) أو بيلة دموية غير جراحية (مصاحبة لأمراض تعدد الكيسات أو الأورام في الجهاز البولي التناسلي). (انظر التحذيرات).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا ينبغي استخدام أميرويك عندما يكون هناك دليل على وجود عملية تخثر نشطة داخل الأوعية الدموية.</p><p dir="RTL">عندما يكون هناك عدم يقين بشأن ما إذا كان سبب النزيف هو انحلال الفايبرين الأساسي أو التخثر المنتشر داخل الأوعية (DIC)، يجب إجراء هذا التمييز قبل إعطاء أميرويك.</p><p dir="RTL">يمكن تطبيق الاختبارات التالية للتمييز بين الحالتين:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عادة ما ينخفض عدد الصفائح الدموية في حالة التخثر المنتشر داخل الأوعية (DIC)ولكنه طبيعي في حالة انحلال الفايبرين الأولي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختبار تجلط الدم بالبروتامين يكون إيجابي في حالة التخثر المنتشر داخل الأوعية (DIC). تتشكل المادة المترسبة عندما يتم اضافة كبريتات البروتامين في البلازما السيترية. يكون الاختبار سلبيًا في حالة وجود انحلال الفايبرين الأولي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختبار تحلل الجلطة الأوجلوبولين غير طبيعي في حالة تحلل الفيبرين الأولي ولكنه طبيعي في حالة التخثر المنتشر داخل الأوعية (DIC).</p><p dir="RTL">يجب عدم استخدام أميرويك في حالة التخثر المنتشر داخل الأوعية (DIC)بدون الهيبارين المصاحب.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL"><strong>احتياطات عامة</strong></p><p dir="RTL">حمض أمينوكابرويك يثبط كلاً من عمل منشطات البلازمينوجين وبدرجة أقل نشاط البلازمين. لا ينبغي إعطاء الدواء دون تشخيص محدد و / أو اكتشاف مختبري يشير إلى انحلال الفيبرين (فرط بلازمين الدم)<sup> 1</sup>.</p><p dir="RTL">قد يؤدي تثبيط انحلال الفيبرين بواسطة حمض أمينوكابرويك نظريًا إلى التخثر. ومع ذلك، لا يوجد دليل واضح على أن إعطاء حمض أمينوكابرويك كان مسؤولاً عن الحالات القليلة المبلغ عنها للتخثر داخل الأوعية الدموية التي أعقبت هذا العلاج. بدلاً من ذلك، يبدو أن مثل هذا التخثر داخل الأوعية كان على الأرجح بسبب الحالة السريرية الموجودة مسبقًا للمريض، على سبيل المثال، وجود حالة التخثر المنتشر داخل الأوعية (DIC). لقد تم افتراض أن الجلطات خارج الأوعية الدموية المتكونة في الجسم الحي قد لا تخضع لتحلل تلقائي كما تفعل الجلطات الطبيعية.</p><p dir="RTL">ظهرت تقارير في المقالات البحثية عن حدوث زيادة في حالات عجز عصبي معين مثل استسقاء الرأس أو نقص تروية الدماغ أو التشنج الدماغي المرتبط باستخدام عوامل تحلل الفايبرين في علاج النزف&nbsp;تحت العنكبوتية في المنطقة الواقعة بين الدماغ والغشاء المحيط (SAH). تم وصف كل هذه الأحداث أيضًا كجزء من المسار الطبيعي لـ SAH، أو كنتيجة لإجراءات تشخيصية مثل تصوير الأوعية. لا يزال ارتباط ذلك بالأدوية غير واضح.</p><p dir="RTL">لا ينبغي استخدام حمض أمينوكابرويك مع مركزات العامل IX المركب (عامل&nbsp;التخثر التاسع) أو مركزات مضادات التخثر المانع للمثبطات، حيث قد يزداد خطر الإصابة بتجلط الدم.</p><p dir="RTL"><strong>الاختبارات المعملية</strong></p><p dir="RTL">يجب أن يكون استخدام حمض أمينوكابرويك مصحوبًا باختبارات مخصصة لتحديد كمية انحلال الفايبرين الموجود. يوجد حاليًا: (أ) اختبارات عامة مثل تلك الخاصة بتحديد تحلل جلطة الدم أو البلازما؛ و (ب) اختبارات أكثر تحديدًا لدراسة المراحل المختلفة لآليات تحلل الفايبرين. تشمل هذه الاختبارات الأخيرة تقنيات نصف كميّة وكميّة لتحديد البروفايبرينوليسين والفايبرينوليسين ومضاد الفايبرينوليسين.</p><p dir="RTL"><strong>تفاعلات اختبار معمل الأدوية</strong></p><p dir="RTL">تم الإبلاغ عن إطالة زمن نزيف الطبيعي أثناء التسريب الوريدي المستمر للحمض أمينوكابرويك بجرعات تزيد عن 24 جم / يوم. لم تظهر دراسات على وظائف الصفائح الدموية في هؤلاء المرضى أي خلل وظيفي كبير في الصفائح الدموية. ومع ذلك، فقد أظهرت الدراسات في المختبر أنه بتركيزات عالية (7.4 ملي مول / لتر أو 0.97 ملغم / مل وأكبر) حمض أمينوكابرويك يثبط ADP وتجمع الصفيحات الناجم عن الكولاجين، وإطلاق ATP والسيروتونين، وربط الفايبرينوجين بالصفائح الدموية في طريقة التركيز والاستجابة. بعد جرعة 10 جم من حمض أمينوكابرويك، تم الحصول على تركيزات بلازما ذروة عابرة تبلغ 4.6 ملي مول / لتر أو 0.60 ملغم / مل. تركيز حمض أمينوكابرويك الضروري للحفاظ على تثبيط انحلال الفايبرين هو 0.99 ملي مول / لتر أو 0.13 ملغم / مل. يجب أن يحقق إعطاء جرعة 5 جم متبوعة بـ 1 إلى 1.25 جم / ساعة مستويات بلازما تبلغ 0.13 ملغم / مل. وبالتالي، فإن التركيزات التي تم الحصول عليها سريريًا في الجسم الحي في المرضى الذين يعانون من وظائف الكلى الطبيعية أقل بكثير من التركيزات في المختبر التي وجدت أنها تسبب شذوذًا في اختبارات وظائف الصفائح الدموية. ومع ذلك، قد تحدث تركيزات أعلى من حمض أمينوكابرويك في البلازما في المرضى الذين يعانون من فشل كلوي حاد.</p><p dir="RTL"><strong>التسرطن، الطفرات، ضعف الخصوبة</strong></p><p dir="RTL">لم يتم إجراء دراسات طويلة الأجل على الحيوانات لتقييم إمكانات حمض أمينوكابرويك المسببة للسرطان ولم يتم إجراء دراسات لتقييم إمكاناته الطفرية. إن إعطاء ما يعادل الحد الأقصى من الجرعة العلاجية البشرية من حمض أمينوكابرويك للفئران من كلا الجنسين يضعف الخصوبة كما يتضح من انخفاض التلقيح، وعدد الجراء المولودين.</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">فئة الحمل ج: لم يتم إجراء دراسات استنساخ الحيوان باستخدام حمض أمينوكابرويك. كما أنه من غير المعروف ما إذا كان حمض أمينوكابرويك يمكن أن يسبب ضررًا للجنين عند إعطائه للمرأة الحامل أو يمكن أن يؤثر على القدرة على الإنجاب. يجب إعطاء حمض أمينوكابرويك للمرأة الحامل فقط إذا لزم الأمر.</p><p dir="RTL"><strong>الأمهات المرضعات</strong></p><p dir="RTL">من غير المعروف ما إذا كان هذا الدواء يُفرز في حليب الأم. نظرًا لأن العديد من الأدوية تُفرز في لبن الإنسان، يجب توخي الحذر عند إعطاء حمض أمينوكابرويك إلى امرأة تمرض.</p><p dir="RTL"><strong>الاستخدام في الأطفال</strong></p><p dir="RTL">لم تثبت سلامة وفعالية مرضى الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن اتباع نظام جرعات مماثل بإعطاء أميرويك على النحو التالي:</p><p dir="RTL">لعلاج متلازمات النزيف الحاد بسبب ارتفاع نشاط تحلل الفايبرين، يُقترح تناول 20 مليلترًا من أميرويك (5 جم) خلال الساعة الأولى من العلاج، متبوعًا بمعدل مستمر قدره 5 مليلتر من أميرويك (1.25 جم) في الساعة. عادة ما تستمر طريقة العلاج هذه لمدة 8 ساعات أو حتى يتم السيطرة على حالة النزيف.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حمض أمينوكابرويك جيد التحمل بشكل عام. تم الإبلاغ عن التجارب السلبية التالية:</p><p dir="RTL"><strong>عام:</strong> وذمة، صداع، توعك.</p><p dir="RTL"><strong>تفاعلات فرط الحساسية:</strong> تفاعلات تحسسية وتأقية، تأق.</p><p dir="RTL"><strong>القلب والأوعية الدموية:</strong> بطء القلب، انخفاض ضغط الدم، نقص التروية المحيطية، تجلط الدم.</p><p dir="RTL"><strong>الجهاز الهضمي:</strong> آلام في البطن، إسهال، غثيان، قيء.</p><p dir="RTL"><strong>أمراض الدم:</strong> ندرة المحببات، اضطراب التخثر، قلة الكريات البيض، قلة الصفيحات.</p><p dir="RTL"><strong>الجهاز العضلي الهيكلي:</strong> زيادة إنزيم &nbsp;CPK ، ضعف العضلات، ألم عضلي، اعتلال عضلي (انظر التحذيرات)، التهاب العضلات، انحلال الربيدات.</p><p dir="RTL"><strong>الجهاز العصبي:</strong> ارتباك، تشنجات، هذيان، دوار، هلوسة، ارتفاع ضغط الدم داخل الجمجمة، جلطة، إغماء.</p><p dir="RTL"><strong>الجهاز التنفسي:</strong> ضيق التنفس، واحتقان الأنف، والانسداد الرئوي.</p><p dir="RTL"><strong>الجلد:</strong> حكة، طفح جلدي.</p><p dir="RTL"><strong>الحواس الخاصة:</strong> طنين الأذن، ضعف الرؤية، دموع في العين.</p><p dir="RTL"><strong>الجهاز البولي التناسلي:</strong> زيادة في اختبار نيتروجين يوريا الدم &quot;BUN&quot; والفشل الكلوي. كانت هناك بعض التقارير عن جفاف القذف خلال فترة العلاج بحمض أمينوكابرويك. تم الإبلاغ عن هذه حتى الآن فقط في مرضى الهيموفيليا الذين تلقوا الدواء بعد خضوعهم لعمليات جراحية في الأسنان. ومع ذلك، تم التعافي من هذه الأعراض في جميع المرضى في غضون 24 إلى 48 ساعة من الانتهاء من العلاج.</p><p><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا ظهرت لديك أي آثار جانبية، تحدث إلى طبيبك أو الصيدلي. يتضمن ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً (انظر التفاصيل أدناه). من خلال الإبلاغ عن التأثيرات الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:576px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال بالهيئة العامة للغذاء والدواء 19999:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني npc.drug@sfda.gov.sa:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دول الخليج العربي الأخرى:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالجهات الوطنية في كل دولة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد EXP. انتهاء الصلاحية يشير التاريخ إلى اليوم الأخير من الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يتطلب هذا الدواء أي شروط تخزين خاصة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لمادة الفعالة هي حمض أمينوكابرويك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل 5 مل من المحلول على 1.25 جم حمض أمينوكابرويك USP</p><p dir="RTL">السواغات الأخرى هي: ميثيل بارابين، بروبيل بارابين، إديتات ثنائي هيدرات ثنائي الصوديوم (تيتريبليكس 3 Emprove)، سكرين الصوديوم، محلول سوربيتول (سوربيتول 71122)، حمض الستريك اللامائي (مسحوق، Emprove)، نكهة التوت AP-888-075-9</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل أميرويك </strong><strong>معلق فموي</strong><strong>؟</strong></p><p dir="RTL">محلول شفاف عديم اللون إلى أصفر قليلاً بنكهة التوت.</p><p dir="RTL"><strong>كيفية توفير أميرويك </strong><strong>معلق فموي</strong><strong>؟</strong></p><p dir="RTL">يتم توفير أميرويك في عبوة زجاجية مصنوعة من&nbsp;&nbsp; HDPE، 8 &nbsp;&nbsp;Fl. Oz (236.5 مل)</p><p><strong>صاحب حق التسويق:</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>صاحب حق التسویق:<br />شركة أماروكس السعودیة للصناعة<br />شارع الجامعة ، حي الملز<br />الریاض ۱۲٦۲۹ ، المملكة العربیة السعودیة<br /><br />المصنع :<br />شركة أنورا فارما الخاصة المحدودة - الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في أبریل ۲۰۲۳ ، نسخة 1
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amiroic (Aminocaproic Acid Oral Solution USP 1.25 g/5 mL)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amiroic (Aminocaproic Acid Oral Solution USP 1.25 g/5 mL) Each 5 mL of solution contains 1.25 g of aminocaproic acid USP
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amiroic (Aminocaproic Acid Oral Solution USP 1.25 g/5 mL)
Clear, colorless to slightly yellow color solution with raspberry flavor.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aminocaproic acid is indicated for use in patients of all ages in haemorrhage caused by local or general fibrinolysis, including in Postsurgical haemorrhages in:</p><p>&bull;&nbsp; Urology (surgery of the bladder and prostate)</p><p>&bull;&nbsp;&nbsp;&nbsp; Gynaecology (cervical surgery), in patients where tranexamic acid is not available or not tolerated</p><p>&bull;&nbsp;&nbsp; Obstetrics (post-partum and post-miscarriage haemorrhages) after correction of the coagulation defect</p><p>&bull;&nbsp; Heart surgery (with or without bypass placement)</p><p>&bull;&nbsp; Gastroenterology</p><p>&bull;&nbsp;&nbsp;&nbsp; Odonto-stomatology (dental extractions in haemophiliacs, patients undergoing anticoagulant therapy) Life-threatening haemorrhages induced by thrombolytics (streptokinase, etc.). Haemorrhages associated with thrombocytopenia, thrombopenic purpura, leukaemia. Nonsurgical haematuria of the lower urinary tract (secondary to cystitis, etc.). Intense menstruations, menorrhagia and haemorrhagic metropathies. Angioneurotic oedema.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An identical dosage regimen may be followed by administering aminocaproic acid oral solution as follows:</p><p>For the treatment of acute bleeding syndromes due to elevated fibrinolytic activity, it is suggested that 20 milli liter of aminocaproic acid oral solution (5 g) be administered during the first hour of treatment, followed by a continuing rate of 5 milliliter of aminocaproic acid oral solution (1.25 g) per hour. This method of treatment would ordinarily be continued for about 8 hours or until the bleeding situation has been controlled.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aminocaproic acid oral solution should not be used when there is evidence of an active intravascular clotting process.
When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering aminocaproic acid oral solution.
The following tests can be applied to differentiate the two conditions:
•	Platelet count is usually decreased in DIC but normal in primary fibrinolysis.
•	Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis.
•	The euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in DIC.
Aminocaproic acid oral solution must not be used in the presence of DIC without concomitant heparin.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In patients with upper urinary tract bleeding, aminocaproic acid administration has been known to cause intrarenal obstruction in the form of glomerular capillary thrombosis or clots in the renal pelvis and ureters. For this reason, aminocaproic acid should not be used in hematuria of upper urinary tract origin, unless the possible benefits outweigh the risk.</p><p>&nbsp;</p><p>&nbsp;</p><p>Subendocardial hemorrhages have been observed in dogs given intravenous infusions of 0.2 times the maximum human therapeutic dose of aminocaproic acid and in monkeys given 8 times the maximum human therapeutic dose of aminocaproic acid.</p><p>Fatty degeneration of the myocardium has been reported in dogs given intravenous doses of aminocaproic acid at 0.8 to 3.3 times the maximum human therapeutic dose and in monkeys given intravenous doses of aminocaproic acid at 6 times the maximum human therapeutic dose. Rarely, skeletal muscle weakness with necrosis of muscle fibers has been reported following prolonged administration. Clinical presentation may range from mild myalgias with weakness and fatigue to a severe proximal myopathy with rhabdomyolysis, myoglobinuria, and acute renal failure. Muscle enzymes, especially creatine phosphokinase (CPK) are elevated. CPK levels should be monitored in patients on long-term therapy. Aminocaproic acid administration should be stopped if a rise in CPK is noted. Resolution follows discontinuation of aminocaproic acid; however, the syndrome may recur if aminocaproic acid is restarted.</p><p>The possibility of cardiac muscle damage should also be considered when skeletal myopathy occurs. One case of cardiac and hepatic lesions observed in man has been reported. The patient received 2 g of aminocaproic acid every 6 hours for a total dose of 26 g. Death was due to continued cerebrovascular hemorrhage. Necrotic changes in the heart and liver were noted at autopsy.</p><p>Precautions</p><p><strong>&nbsp;</strong></p><p>General</p><p>Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The drug should NOT be administered without a definite diagnosis and/or laboratory finding indicative of hyper fibrinolysis (hyperplasminemia).</p><p>Inhibition of fibrinolysis by aminocaproic acid may theoretically result in clotting or thrombosis. However, there is no definite evidence that administration of aminocaproic acid has been responsible for the few reported cases of intravascular clotting which followed this treatment. Rather, it appears that such intravascular clotting was most likely due to the patient&#39;s pre - existing clinical condition, e.g., the presence of DIC. It has been postulated that extravascular clots formed <em>in vivo </em>may not undergo spontaneous lysis as do normal clots.</p><p>&nbsp;</p><p>&nbsp;</p><p>Reports have appeared in the literature of an increased incidence of certain neurological deficits such as hydrocephalus, cerebral ischemia, or cerebral vasospasm associated with the use of antifibrinolytic agents in the treatment of subarachnoid hemorrhage (SAH). All of these events have also been described as part of the natural course of SAH, or as a consequence of diagnostic procedures such as angiography. Drug relatedness remains unclear.</p><p>Aminocaproic acid should not be administered with Factor IX Complex concentrates or Anti- Inhibitor Coagulant concentrates, as the risk of thrombosis may be increased.</p><p>Laboratory Tests</p><p>The use of aminocaproic acid should be accompanied by tests designed to determine the amount of fibrinolysis present. There are presently available: (a) general tests such as those for the determination of the lysis of a clot of blood or plasma; and (b) more specific tests for the study of various phases of the fibrinolytic mechanisms. These latter tests include both semiquantitative and quantitative techniques for the determination of profibrinolysin, fibrinolysin, and antifibrinolysin.</p><p>Drug Laboratory Test Interactions</p><p>Prolongation of the template bleeding time has been reported during continuous intravenous infusion of aminocaproic acid at dosages exceeding 24 g/day. Platelet function studies in these patients have not demonstrated any significant platelet dysfunction. However, <em>in vitro </em>studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) aminocaproic acid inhibits ADP and collagen-induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner. Following a 10 g bolus of aminocaproic acid, transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained. The concentration of aminocaproic acid necessary to maintain inhibition of fibrinolysis is 0.99 mMol/L or 0.13 mg/mL. Administration of a 5 g bolus followed by 1 to 1.25 g/hr should achieve and sustain plasma levels of 0.13 mg/mL. Thus, concentrations which have been obtained <em>in vivo </em>clinically in patients with normal renal function are considerably lower than the <em>in vitro </em>concentrations found to induce abnormalities in platelet function tests. However, higher plasma concentrations of aminocaproic acid may occur in patients with severe renal failure.</p><p>&nbsp;</p><p>&nbsp;</p><p>Carcinogenesis, Mutagenesis, Impairment of Fertility</p><p>Long-term studies in animals to evaluate the carcinogenic potential of aminocaproic acid and studies to evaluate its mutagenic potential have not been conducted. Dietary administration of an equivalent of the maximum human therapeutic dose of aminocaproic acid to rats of both sexes impaired fertility as evidenced by decreased implantations, litter sizes and number of pups born. <strong><em>Pregnancy</em></strong></p><p><em>Pregnancy Category C</em>. Animal reproduction studies have not been conducted with aminocaproic acid. It is also not known whether aminocaproic acid can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Aminocaproic acid should be given to a pregnant woman only if clearly needed.</p><p>Nursing Mothers</p><p>It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when aminocaproic acid is administered to a nursing woman.</p><p>Pediatric Use</p><p>Safety and effectiveness in pediatric patients have not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pregnancy</em></strong></p><p><em>Pregnancy Category C</em>. Animal reproduction studies have not been conducted with aminocaproic acid. It is also not known whether aminocaproic acid can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Aminocaproic acid should be given to a pregnant woman only if clearly needed.</p><p>Nursing Mothers</p><p>It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when aminocaproic acid is administered to a nursing woman.</p><p>Pediatric Use</p><p>Safety and effectiveness in pediatric patients have not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aminocaproic acid is generally well tolerated. The following adverse experiences have been reported:</p><p><strong>General: </strong>Edema, headache, malaise.</p><p><strong>Hypersensitivity Reactions: </strong>Allergic and anaphylactoid reactions, anaphylaxis.</p><p><strong>Cardiovascular: </strong>Bradycardia, hypotension, peripheral ischemia, thrombosis.</p><p><strong>Gastrointestinal: </strong>Abdominal pain, diarrhoea, nausea, vomiting.</p><p><strong>Hematologic: </strong>Agranulocytosis, coagulation disorder, leukopenia, thrombocytopenia.</p><p><strong>Musculoskeletal: </strong>CPK increased, muscle weakness, myalgia, myopathy (see <strong><u>WARNINGS</u></strong>), myositis, rhabdomyolysis.</p><p><strong>Neurologic: </strong>Confusion, convulsions, delirium, dizziness, hallucinations, intracranial hypertension, stroke, syncope.</p><p><strong>Respiratory: </strong>Dyspnea, nasal congestion, pulmonary embolism.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Skin: </strong>Pruritis, rash.</p><p><strong>Special Senses: </strong>Tinnitus, vision decreased, watery eyes.</p><p><strong>Urogenital: </strong>BUN increased, renal failure. There have been some reports of dry ejaculation during the period of aminocaproic acid treatment. These have been reported to date only in hemophilia patients who received the drug after undergoing dental surgical procedures. However, this symptom resolved in all patients within 24 to 48 hours of completion of therapy.</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>&bull;&nbsp; Saudi Arabia<em>:</em></p><p><strong><em>&nbsp;</em></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:122.9pt;margin-top:9.7pt;width:402.4pt;height:106.95pt;z-index:-251656192;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".16969mm">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:0in;margin-right:81.7pt;margin-bottom:
     0in;margin-left:10.3pt;margin-bottom:.0001pt;line-height:193%'>The
     National Pharmacovigilance and Drug Safety Centre (NPC) o SFDA Call
     Center: 19999<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:19.3pt;text-indent:-9.2pt;
     line-height:13.65pt;mso-line-height-rule:exactly;mso-list:l0 level1 lfo1;
     tab-stops:19.35pt'><![if !supportLists]><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><![endif]><span
     dir=LTR></span><a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>E-mail:npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.9pt;margin-right:0in;margin-bottom:
     0in;margin-left:19.3pt;margin-bottom:.0001pt;text-indent:-9.2pt;
     mso-list:l0 level1 lfo1;tab-stops:19.35pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>Website:https://ade.sfda.gov.sa/<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="541" height="147" alt="Text Box: The National Pharmacovigilance and Drug Safety Centre (NPC) o SFDA Call Center: 19999
o	E-mail:npc.drug@sfda.gov.sa
o	Website:https://ade.sfda.gov.sa/
" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><strong>o Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A few cases of acute over dosage with aminocaproic acid administered intravenously have been reported. The effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to death. One patient with a history of brain tumor and seizures experienced seizures after receiving an 8gram bolus injection of aminocaproic acid. The single dose of aminocaproic acid causing symptoms of over dosage or considered to be life-threatening is unknown. Patients have tolerated doses as high as 100 grams while acute renal failure has been reported following a dose of 12 grams.</p><p>&nbsp;</p><p>&nbsp;</p><p>The intravenous and oral LD50 of aminocaproic acid were 3.0 and 12.0 g/kg, respectively, in the mouse and 3.2 and 16.4 g/kg, respectively, in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog. On intravenous administration, tonic-clonic convulsions were observed in dogs and mice.</p><p>No treatment for over dosage is known, although evidence exists that aminocaproic acid is removed by hemodialysis and may be removed by peritoneal dialysis. Pharmacokinetic studies have shown that total body clearance of aminocaproic acid is markedly decreased in patients with severe renal failure.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antifibrinolytic Agent ATC code: B02AA01</p><p><u>Mechanism of action</u></p><p>The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1). Mean &plusmn; SD peak plasma concentrations (164 &plusmn; 28 mcg/mL) were reached within 1.2 &plusmn; 0.45 hours.</p><p><u>Distribution</u></p><p>After oral administration, the apparent volume of distribution was estimated to be 23.1 &plusmn; 6.6 L (mean &plusmn; SD). Correspondingly, the volume of distribution after intravenous administration has been reported to be 30.0 &plusmn; 8.2 L. After prolonged administration, aminocaproic acid has been found to distribute throughout extravascular and intravascular compartments of the body, penetrating human red blood cells as well as other tissue cells.</p><p><u>Elimination</u></p><p>Renal excretion is the primary route of elimination. Sixty-five percent of the dose is recovered in the urine as unchanged drug and 11% of the dose appears as the metabolite adipic acid. Renal clearance (116 mL/min) approximates endogenous creatinine clearance. The total body clearance</p><p>&nbsp;</p><p>&nbsp;</p><p>is 169 mL/min. The terminal elimination half-life for aminocaproic acid is approximately 2 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Methyl paraben, Propyl paraben, Edetate disodium dihydrate (Titriplex III Emprove), Saccharin Sodium, Sorbitol solution (Sorbidex 71122), Anhydrous Citric Acid (Powder, Emprove), Raspberry flavor AP-888-075-9</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p><p>Dispense in Tight Containers; Do Not Freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>8 Fl. oz. (236.5 mL) in HDPE Bottle Pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company,
Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia
Tel: +966 11 477 2215
Manufacture:
Annora Pharma Private Limited, India

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December, 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>